Prognostic Validation of the Body Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity (BODE) Index in Inoperable Non–Small-Cell Lung Cancer
To investigate the prognostic utility of the body mass index, severity of airflow obstruction, measures of exertional dyspnea, and exercise capacity (BODE) index in patients with inoperable non–small-cell lung cancer (NSCLC). One hundred consecutive patients with inoperable NSCLC and performance sta...
Gespeichert in:
Veröffentlicht in: | Journal of thoracic oncology 2013-12, Vol.8 (12), p.1545-1550 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1550 |
---|---|
container_issue | 12 |
container_start_page | 1545 |
container_title | Journal of thoracic oncology |
container_volume | 8 |
creator | Denehy, Linda Hornsby, Whitney E. Herndon, James E. Thomas, Samantha Ready, Neal E. Granger, Catherine L. Valera, Lauren Kenjale, Aarti A. Eves, Neil D. Jones, Lee W. |
description | To investigate the prognostic utility of the body mass index, severity of airflow obstruction, measures of exertional dyspnea, and exercise capacity (BODE) index in patients with inoperable non–small-cell lung cancer (NSCLC).
One hundred consecutive patients with inoperable NSCLC and performance status 0 to 3 completed pulmonary function testing, the modified Medical Research Council dyspnea scale, a 6-minute walk test, and body mass index—the multidimensional 10-point BODE index. Cox proportional models were used to estimate the risk of all-cause mortality according to the BODE index with or without adjustment for traditional prognostic factors.
Median follow-up was 31.5 months; 61 deaths (61%) were reported during this period. There was a significant univariate association between the BODE index score and mortality (adjusted ptrend = 0.027). Compared with patients with a BODE index of 0, the adjusted hazard ratio for risk of death was 1.37 (95% confidence interval [CI], 0.74–2.55) for a BODE index of 1, 1.22 (95% CI, 0.45–3.25) for a BODE index of 2, and 2.44 (95% CI, 1.19–4.99) for a BODE index more than 2. The BODE index provided incremental prognostic information beyond that provided traditional markers of prognosis (adjusted ptrend = 0.051). Every one-point increase in the BODE index, the risk of death increased by 25% (hazard ratio = 1.25; 95% CI, 1.27–4.64).
The BODE index is a strong independent predictor of survival in inoperable NSCLC beyond traditional risk factors. Use of this multidimensional tool may improve risk stratification and prognostication in NSCLC. |
doi_str_mv | 10.1097/JTO.0000000000000032 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1490750485</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1556086415301374</els_id><sourcerecordid>1490750485</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-e580c9bf6ab592750cc53c8fb4cbaa6efd50419d7369b60217a89abe050e4e923</originalsourceid><addsrcrecordid>eNp9kctu1DAUhi0Eohf6BqjyspUmxUnsJN4gtdMpFA2dSi1sLV9OWqOMndoJdHZ9B1a8Hk-CRzMgwYKzOWfx_ef2I_Q6Jyc54fWbD7eLE_JXlMUztJszVmV52ZDn25o0Fd1BezF-IYQyQpuXaKegZcNpWe2iH9fB3zkfB6vxZ9lZIwfrHfYtHu4Bn3mzwh9ljPjSGXic4FMb2s5_wwsVhzDqNTvB56vYO5ATLJ3Bs0cI2kbAU9lLbYcVPjpbnM-ONx2wdanwPQSpOsBX3v18-n6zlF2XTaHr8Hx0d0npNIRX6EUruwgH27yPPl3Mbqfvs_ni3eX0dJ5pWtMhA9YQzVVbScV4UTOiNSt10yqqlZQVtCbdnHNTlxVXFSnyWjZcKiCMAAVelPvoaNO3D_5hhDiIpY06LSMd-DGKnHJSr__GEko3qA4-xgCt6INdyrASORFrU0QyRfxrSpIdbieMagnmj-i3Cwl4uwEg3fnVQhBRW0hPMDaAHoTx9v8TfgFut5wi</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1490750485</pqid></control><display><type>article</type><title>Prognostic Validation of the Body Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity (BODE) Index in Inoperable Non–Small-Cell Lung Cancer</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><source>Journals@Ovid Complete</source><creator>Denehy, Linda ; Hornsby, Whitney E. ; Herndon, James E. ; Thomas, Samantha ; Ready, Neal E. ; Granger, Catherine L. ; Valera, Lauren ; Kenjale, Aarti A. ; Eves, Neil D. ; Jones, Lee W.</creator><creatorcontrib>Denehy, Linda ; Hornsby, Whitney E. ; Herndon, James E. ; Thomas, Samantha ; Ready, Neal E. ; Granger, Catherine L. ; Valera, Lauren ; Kenjale, Aarti A. ; Eves, Neil D. ; Jones, Lee W.</creatorcontrib><description>To investigate the prognostic utility of the body mass index, severity of airflow obstruction, measures of exertional dyspnea, and exercise capacity (BODE) index in patients with inoperable non–small-cell lung cancer (NSCLC).
One hundred consecutive patients with inoperable NSCLC and performance status 0 to 3 completed pulmonary function testing, the modified Medical Research Council dyspnea scale, a 6-minute walk test, and body mass index—the multidimensional 10-point BODE index. Cox proportional models were used to estimate the risk of all-cause mortality according to the BODE index with or without adjustment for traditional prognostic factors.
Median follow-up was 31.5 months; 61 deaths (61%) were reported during this period. There was a significant univariate association between the BODE index score and mortality (adjusted ptrend = 0.027). Compared with patients with a BODE index of 0, the adjusted hazard ratio for risk of death was 1.37 (95% confidence interval [CI], 0.74–2.55) for a BODE index of 1, 1.22 (95% CI, 0.45–3.25) for a BODE index of 2, and 2.44 (95% CI, 1.19–4.99) for a BODE index more than 2. The BODE index provided incremental prognostic information beyond that provided traditional markers of prognosis (adjusted ptrend = 0.051). Every one-point increase in the BODE index, the risk of death increased by 25% (hazard ratio = 1.25; 95% CI, 1.27–4.64).
The BODE index is a strong independent predictor of survival in inoperable NSCLC beyond traditional risk factors. Use of this multidimensional tool may improve risk stratification and prognostication in NSCLC.</description><identifier>ISSN: 1556-0864</identifier><identifier>EISSN: 1556-1380</identifier><identifier>DOI: 10.1097/JTO.0000000000000032</identifier><identifier>PMID: 24389436</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adenocarcinoma - complications ; Adenocarcinoma - mortality ; Adenocarcinoma - pathology ; Adenocarcinoma, Bronchiolo-Alveolar - complications ; Adenocarcinoma, Bronchiolo-Alveolar - mortality ; Adenocarcinoma, Bronchiolo-Alveolar - pathology ; Adult ; Aged ; Aged, 80 and over ; Airway Obstruction - etiology ; Airway Obstruction - mortality ; Airway Obstruction - physiopathology ; Body Mass Index ; Carcinoma, Non-Small-Cell Lung - complications ; Carcinoma, Non-Small-Cell Lung - mortality ; Carcinoma, Non-Small-Cell Lung - pathology ; Carcinoma, Squamous Cell - complications ; Carcinoma, Squamous Cell - mortality ; Carcinoma, Squamous Cell - pathology ; Dyspnea - etiology ; Dyspnea - mortality ; Dyspnea - physiopathology ; Exercise ; Exercise Tolerance ; Female ; Follow-Up Studies ; Humans ; Lung cancer ; Lung Neoplasms - complications ; Lung Neoplasms - mortality ; Lung Neoplasms - pathology ; Male ; Middle Aged ; Neoplasm Staging ; Prognosis ; Respiratory Function Tests ; Survival ; Survival Rate</subject><ispartof>Journal of thoracic oncology, 2013-12, Vol.8 (12), p.1545-1550</ispartof><rights>2013 International Association for the Study of Lung Cancer</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-e580c9bf6ab592750cc53c8fb4cbaa6efd50419d7369b60217a89abe050e4e923</citedby><cites>FETCH-LOGICAL-c474t-e580c9bf6ab592750cc53c8fb4cbaa6efd50419d7369b60217a89abe050e4e923</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24389436$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Denehy, Linda</creatorcontrib><creatorcontrib>Hornsby, Whitney E.</creatorcontrib><creatorcontrib>Herndon, James E.</creatorcontrib><creatorcontrib>Thomas, Samantha</creatorcontrib><creatorcontrib>Ready, Neal E.</creatorcontrib><creatorcontrib>Granger, Catherine L.</creatorcontrib><creatorcontrib>Valera, Lauren</creatorcontrib><creatorcontrib>Kenjale, Aarti A.</creatorcontrib><creatorcontrib>Eves, Neil D.</creatorcontrib><creatorcontrib>Jones, Lee W.</creatorcontrib><title>Prognostic Validation of the Body Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity (BODE) Index in Inoperable Non–Small-Cell Lung Cancer</title><title>Journal of thoracic oncology</title><addtitle>J Thorac Oncol</addtitle><description>To investigate the prognostic utility of the body mass index, severity of airflow obstruction, measures of exertional dyspnea, and exercise capacity (BODE) index in patients with inoperable non–small-cell lung cancer (NSCLC).
One hundred consecutive patients with inoperable NSCLC and performance status 0 to 3 completed pulmonary function testing, the modified Medical Research Council dyspnea scale, a 6-minute walk test, and body mass index—the multidimensional 10-point BODE index. Cox proportional models were used to estimate the risk of all-cause mortality according to the BODE index with or without adjustment for traditional prognostic factors.
Median follow-up was 31.5 months; 61 deaths (61%) were reported during this period. There was a significant univariate association between the BODE index score and mortality (adjusted ptrend = 0.027). Compared with patients with a BODE index of 0, the adjusted hazard ratio for risk of death was 1.37 (95% confidence interval [CI], 0.74–2.55) for a BODE index of 1, 1.22 (95% CI, 0.45–3.25) for a BODE index of 2, and 2.44 (95% CI, 1.19–4.99) for a BODE index more than 2. The BODE index provided incremental prognostic information beyond that provided traditional markers of prognosis (adjusted ptrend = 0.051). Every one-point increase in the BODE index, the risk of death increased by 25% (hazard ratio = 1.25; 95% CI, 1.27–4.64).
The BODE index is a strong independent predictor of survival in inoperable NSCLC beyond traditional risk factors. Use of this multidimensional tool may improve risk stratification and prognostication in NSCLC.</description><subject>Adenocarcinoma - complications</subject><subject>Adenocarcinoma - mortality</subject><subject>Adenocarcinoma - pathology</subject><subject>Adenocarcinoma, Bronchiolo-Alveolar - complications</subject><subject>Adenocarcinoma, Bronchiolo-Alveolar - mortality</subject><subject>Adenocarcinoma, Bronchiolo-Alveolar - pathology</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Airway Obstruction - etiology</subject><subject>Airway Obstruction - mortality</subject><subject>Airway Obstruction - physiopathology</subject><subject>Body Mass Index</subject><subject>Carcinoma, Non-Small-Cell Lung - complications</subject><subject>Carcinoma, Non-Small-Cell Lung - mortality</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Carcinoma, Squamous Cell - complications</subject><subject>Carcinoma, Squamous Cell - mortality</subject><subject>Carcinoma, Squamous Cell - pathology</subject><subject>Dyspnea - etiology</subject><subject>Dyspnea - mortality</subject><subject>Dyspnea - physiopathology</subject><subject>Exercise</subject><subject>Exercise Tolerance</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Lung cancer</subject><subject>Lung Neoplasms - complications</subject><subject>Lung Neoplasms - mortality</subject><subject>Lung Neoplasms - pathology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Prognosis</subject><subject>Respiratory Function Tests</subject><subject>Survival</subject><subject>Survival Rate</subject><issn>1556-0864</issn><issn>1556-1380</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kctu1DAUhi0Eohf6BqjyspUmxUnsJN4gtdMpFA2dSi1sLV9OWqOMndoJdHZ9B1a8Hk-CRzMgwYKzOWfx_ef2I_Q6Jyc54fWbD7eLE_JXlMUztJszVmV52ZDn25o0Fd1BezF-IYQyQpuXaKegZcNpWe2iH9fB3zkfB6vxZ9lZIwfrHfYtHu4Bn3mzwh9ljPjSGXic4FMb2s5_wwsVhzDqNTvB56vYO5ATLJ3Bs0cI2kbAU9lLbYcVPjpbnM-ONx2wdanwPQSpOsBX3v18-n6zlF2XTaHr8Hx0d0npNIRX6EUruwgH27yPPl3Mbqfvs_ni3eX0dJ5pWtMhA9YQzVVbScV4UTOiNSt10yqqlZQVtCbdnHNTlxVXFSnyWjZcKiCMAAVelPvoaNO3D_5hhDiIpY06LSMd-DGKnHJSr__GEko3qA4-xgCt6INdyrASORFrU0QyRfxrSpIdbieMagnmj-i3Cwl4uwEg3fnVQhBRW0hPMDaAHoTx9v8TfgFut5wi</recordid><startdate>20131201</startdate><enddate>20131201</enddate><creator>Denehy, Linda</creator><creator>Hornsby, Whitney E.</creator><creator>Herndon, James E.</creator><creator>Thomas, Samantha</creator><creator>Ready, Neal E.</creator><creator>Granger, Catherine L.</creator><creator>Valera, Lauren</creator><creator>Kenjale, Aarti A.</creator><creator>Eves, Neil D.</creator><creator>Jones, Lee W.</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20131201</creationdate><title>Prognostic Validation of the Body Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity (BODE) Index in Inoperable Non–Small-Cell Lung Cancer</title><author>Denehy, Linda ; Hornsby, Whitney E. ; Herndon, James E. ; Thomas, Samantha ; Ready, Neal E. ; Granger, Catherine L. ; Valera, Lauren ; Kenjale, Aarti A. ; Eves, Neil D. ; Jones, Lee W.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-e580c9bf6ab592750cc53c8fb4cbaa6efd50419d7369b60217a89abe050e4e923</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adenocarcinoma - complications</topic><topic>Adenocarcinoma - mortality</topic><topic>Adenocarcinoma - pathology</topic><topic>Adenocarcinoma, Bronchiolo-Alveolar - complications</topic><topic>Adenocarcinoma, Bronchiolo-Alveolar - mortality</topic><topic>Adenocarcinoma, Bronchiolo-Alveolar - pathology</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Airway Obstruction - etiology</topic><topic>Airway Obstruction - mortality</topic><topic>Airway Obstruction - physiopathology</topic><topic>Body Mass Index</topic><topic>Carcinoma, Non-Small-Cell Lung - complications</topic><topic>Carcinoma, Non-Small-Cell Lung - mortality</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Carcinoma, Squamous Cell - complications</topic><topic>Carcinoma, Squamous Cell - mortality</topic><topic>Carcinoma, Squamous Cell - pathology</topic><topic>Dyspnea - etiology</topic><topic>Dyspnea - mortality</topic><topic>Dyspnea - physiopathology</topic><topic>Exercise</topic><topic>Exercise Tolerance</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Lung cancer</topic><topic>Lung Neoplasms - complications</topic><topic>Lung Neoplasms - mortality</topic><topic>Lung Neoplasms - pathology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Prognosis</topic><topic>Respiratory Function Tests</topic><topic>Survival</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Denehy, Linda</creatorcontrib><creatorcontrib>Hornsby, Whitney E.</creatorcontrib><creatorcontrib>Herndon, James E.</creatorcontrib><creatorcontrib>Thomas, Samantha</creatorcontrib><creatorcontrib>Ready, Neal E.</creatorcontrib><creatorcontrib>Granger, Catherine L.</creatorcontrib><creatorcontrib>Valera, Lauren</creatorcontrib><creatorcontrib>Kenjale, Aarti A.</creatorcontrib><creatorcontrib>Eves, Neil D.</creatorcontrib><creatorcontrib>Jones, Lee W.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of thoracic oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Denehy, Linda</au><au>Hornsby, Whitney E.</au><au>Herndon, James E.</au><au>Thomas, Samantha</au><au>Ready, Neal E.</au><au>Granger, Catherine L.</au><au>Valera, Lauren</au><au>Kenjale, Aarti A.</au><au>Eves, Neil D.</au><au>Jones, Lee W.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic Validation of the Body Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity (BODE) Index in Inoperable Non–Small-Cell Lung Cancer</atitle><jtitle>Journal of thoracic oncology</jtitle><addtitle>J Thorac Oncol</addtitle><date>2013-12-01</date><risdate>2013</risdate><volume>8</volume><issue>12</issue><spage>1545</spage><epage>1550</epage><pages>1545-1550</pages><issn>1556-0864</issn><eissn>1556-1380</eissn><abstract>To investigate the prognostic utility of the body mass index, severity of airflow obstruction, measures of exertional dyspnea, and exercise capacity (BODE) index in patients with inoperable non–small-cell lung cancer (NSCLC).
One hundred consecutive patients with inoperable NSCLC and performance status 0 to 3 completed pulmonary function testing, the modified Medical Research Council dyspnea scale, a 6-minute walk test, and body mass index—the multidimensional 10-point BODE index. Cox proportional models were used to estimate the risk of all-cause mortality according to the BODE index with or without adjustment for traditional prognostic factors.
Median follow-up was 31.5 months; 61 deaths (61%) were reported during this period. There was a significant univariate association between the BODE index score and mortality (adjusted ptrend = 0.027). Compared with patients with a BODE index of 0, the adjusted hazard ratio for risk of death was 1.37 (95% confidence interval [CI], 0.74–2.55) for a BODE index of 1, 1.22 (95% CI, 0.45–3.25) for a BODE index of 2, and 2.44 (95% CI, 1.19–4.99) for a BODE index more than 2. The BODE index provided incremental prognostic information beyond that provided traditional markers of prognosis (adjusted ptrend = 0.051). Every one-point increase in the BODE index, the risk of death increased by 25% (hazard ratio = 1.25; 95% CI, 1.27–4.64).
The BODE index is a strong independent predictor of survival in inoperable NSCLC beyond traditional risk factors. Use of this multidimensional tool may improve risk stratification and prognostication in NSCLC.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>24389436</pmid><doi>10.1097/JTO.0000000000000032</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1556-0864 |
ispartof | Journal of thoracic oncology, 2013-12, Vol.8 (12), p.1545-1550 |
issn | 1556-0864 1556-1380 |
language | eng |
recordid | cdi_proquest_miscellaneous_1490750485 |
source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection; Journals@Ovid Complete |
subjects | Adenocarcinoma - complications Adenocarcinoma - mortality Adenocarcinoma - pathology Adenocarcinoma, Bronchiolo-Alveolar - complications Adenocarcinoma, Bronchiolo-Alveolar - mortality Adenocarcinoma, Bronchiolo-Alveolar - pathology Adult Aged Aged, 80 and over Airway Obstruction - etiology Airway Obstruction - mortality Airway Obstruction - physiopathology Body Mass Index Carcinoma, Non-Small-Cell Lung - complications Carcinoma, Non-Small-Cell Lung - mortality Carcinoma, Non-Small-Cell Lung - pathology Carcinoma, Squamous Cell - complications Carcinoma, Squamous Cell - mortality Carcinoma, Squamous Cell - pathology Dyspnea - etiology Dyspnea - mortality Dyspnea - physiopathology Exercise Exercise Tolerance Female Follow-Up Studies Humans Lung cancer Lung Neoplasms - complications Lung Neoplasms - mortality Lung Neoplasms - pathology Male Middle Aged Neoplasm Staging Prognosis Respiratory Function Tests Survival Survival Rate |
title | Prognostic Validation of the Body Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity (BODE) Index in Inoperable Non–Small-Cell Lung Cancer |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T06%3A18%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20Validation%20of%20the%20Body%20Mass%20Index,%20Airflow%20Obstruction,%20Dyspnea,%20and%20Exercise%20Capacity%20(BODE)%20Index%20in%20Inoperable%20Non%E2%80%93Small-Cell%20Lung%20Cancer&rft.jtitle=Journal%20of%20thoracic%20oncology&rft.au=Denehy,%20Linda&rft.date=2013-12-01&rft.volume=8&rft.issue=12&rft.spage=1545&rft.epage=1550&rft.pages=1545-1550&rft.issn=1556-0864&rft.eissn=1556-1380&rft_id=info:doi/10.1097/JTO.0000000000000032&rft_dat=%3Cproquest_cross%3E1490750485%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1490750485&rft_id=info:pmid/24389436&rft_els_id=S1556086415301374&rfr_iscdi=true |